TRAW$0.31+3.23%
Traws Pharma, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$4.76M
Float & O/S:
Inst Own:
DilutionScan read 36 of Traws Pharma, Inc.'s SEC filings and found 9 warrant series, 1 convertible, 1 ATM program, 1 equity line, 5 shelf registrations, 1 S-1 registration and 1 completed offering on file for TRAW. The latest dilution event on file is a registration statement on Oct 26, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
TRAW
Going-concern warning, clinical hold, tiny cash
Snapshot
Traws is a clinical-stage biotech with no meaningful revenue and a going-concern warning from its own filings: just $3.1M in cash against a business burning roughly $20.8M a year in free cash flow.
What's Happening Right Now
- : The Q2 2026 10-Q disclosed substantial doubt about continuing as a going concern, with $5.0M cash against a $650.1M accumulated deficit, plus an FDA clinical hold on lead drug tivoxavir marboxil and a UK MHRA deferral of its planned trial.
- : Q2 2026 revenue fell to zero from $2.7M a year earlier, net loss widened to $3.0M, and management said cash plus planned ATM sales fund operations only into Q1 2027 without more financing.
- : Nasdaq notified Traws it is out of compliance with the $1.00 minimum bid price rule, giving the company until January 25, 2027 to regain compliance or face delisting risk.
- : Traws filed a prospectus supplement to sell up to $5.6M of stock via an at-the-market program, again flagging going-concern doubt with cash sufficient only into Q1 2027.
- : At the July 8, 2026 annual meeting, shareholders approved Series B and C warrant tranches from the April 2026 financing and increased incentive plan shares by 2,000,000.
- : Registered $139.19M of securities for sale on Form S-3.
- : Sold $2.02M of stock / 1.19M shares through its at-the-market program.
- : Registered additional securities for sale on Form S-3.
